The approval was supported by data from the randomized, double-blind, placebo-controlled, phase 3 ARANOTE trial.

The OPTIS insert is claimed to help them do so, by serving as an inflatable alternative to foam-bodied tubeless tire inserts. So first of all, if you're unfamiliar with the selling points of ...

With the release candidate version 2 presented last week, Apple also provided a package insert for the first time. This contains an overview of the new features. It includes some exciting details ...

Darolutamide plus androgen-deprivation therapy (ADT) with docetaxel improved OS versus ADT and docetaxel in patients with mHSPC. The ARANOTE trial evaluated darolutamide and ADT without ...

Bayer announced the submission of an application to the European Medicines Agency (EMA) for the oral androgen receptor inhibitor (ARi) darolutamide. Bayer is seeking approval for the use of ...

(RTTNews) - Bayer announced the submission of an application to the European Medicines Agency for the oral androgen receptor inhibitor darolutamide. The company is seeking approval for the use of ...

Bayer has submitted an EMA application for darolutamide combined with ADT for metastatic hormone-sensitive prostate cancer. The Phase 3 ARANOTE trial showed darolutamide with ADT reduced ...

Darolutamide plus androgen deprivation therapy (ADT), without docetaxel, significantly prolonged radiographic progression-free survival compared with placebo plus ADT in patients with metastatic ...

It is possible to turn on or off overtype mode and allow the Insert key to activate the overtype mode in Word with the help of the in-built option. This explains everything about the overtype mode ...

Whole Lung Irradiation in Rhabdomyosarcoma With Lung Metastases: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group From March 2021 to August 2022, 669 patients were ...

The phase III ARANOTE trial, investigating darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC), has met its primary endpoint of rPFS. Darolutamide plus ADT ...

Bayer and Orion’s darolutamide has demonstrated significant survival benefits as part of a combination treatment in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to new ...